JP2527958B2 - Central nervous system treatment - Google Patents
Central nervous system treatmentInfo
- Publication number
- JP2527958B2 JP2527958B2 JP62077569A JP7756987A JP2527958B2 JP 2527958 B2 JP2527958 B2 JP 2527958B2 JP 62077569 A JP62077569 A JP 62077569A JP 7756987 A JP7756987 A JP 7756987A JP 2527958 B2 JP2527958 B2 JP 2527958B2
- Authority
- JP
- Japan
- Prior art keywords
- pyrrolidone
- nervous system
- central nervous
- therapeutic agent
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【発明の詳細な説明】 〔産業上の利用分野〕 本発明は中枢神経障害治療剤に関する。更に詳しく
は、本発明は特定のＮ−アシル−２−ピロリドン類を有
効成分とする新規な中枢神経障害治療剤に関する。TECHNICAL FIELD The present invention relates to a therapeutic agent for central nervous system disorders. More specifically, the present invention relates to a novel therapeutic agent for central nervous system disorders containing a specific N-acyl-2-pyrrolidone compound as an active ingredient.
γ−アミノ酪酸（以下GABAと略記する）は中枢神経系
に存在するアミノ酸であって、NH2CH2CH2CH2COOHなる化
学式を持つ化学物質である。γ-Aminobutyric acid (hereinafter abbreviated as GABA) is an amino acid existing in the central nervous system and is a chemical substance having a chemical formula of NH 2 CH 2 CH 2 CH 2 COOH.
このGABAは以前より抑制性神経伝達物質として注目さ
れ、その薬理作用も極めて興味深いものがあるが、GABA
には自身が極性物質であるため血液脳関門を通過し難
く、作用も弱いという特性があり、これを克服しないと
医薬としての活用が望めないという問題点を持ってい
る。GABA has been attracting attention as an inhibitory neurotransmitter for some time, and its pharmacological action is extremely interesting.
Has a characteristic that it is difficult to cross the blood-brain barrier and its action is weak because it is a polar substance, and it has a problem that it cannot be used as a medicine unless it is overcome.
そこで、GABAの脂溶性誘導体を開発する等の開発努力
が重ねられ、それらの中から、近年GABA関連物質として
抗痙攣薬や脳内代謝賦活薬等が臨床的に使用されるとい
う成果が出はじめている。Therefore, development efforts such as the development of fat-soluble derivatives of GABA have been repeated, and among them, in recent years, the results of clinical use of anticonvulsant drugs and brain metabolism activating drugs as GABA-related substances have begun to appear. There is.
本発明は上記したGABAが抱える問題点、すなわち血液
脳関門を通過し難いという点を克服し、且つ、GABAが持
っている中枢神経系に対する種々の作用効果を発現を可
能にした中枢神経障害の新規な治療剤を開発することを
目的としてなされたものである。The present invention overcomes the above-mentioned problems that GABA has, that is, it is difficult to cross the blood-brain barrier, and GABA has various central and nervous system effects that enable expression of central nervous system disorders. It was made for the purpose of developing a new therapeutic agent.
本発明者らは上記の目的を達成すべく鋭意検討を重ね
た結果、GABAの環状誘導体である２−ピロリドンが検討
すべき物質であることを確認し、その誘導体を種々探究
したところ、特定のＮ−アシル−２−ピロリドンが鎮痛
・鎮静作用及び催眠作用及び抗痙攣作用等、中枢神経系
に対し抑制的な作用を示すとともに、抗健忘作用等の中
枢神経系に対する賦活的な作用も示すことを見出し、こ
れらの知見に基づいて本発明を完成した。As a result of intensive studies to achieve the above-mentioned objects, the present inventors have confirmed that 2-pyrrolidone, which is a cyclic derivative of GABA, is a substance to be investigated, and variously investigated the derivative, and found that N-acyl-2-pyrrolidone has an inhibitory effect on the central nervous system such as analgesic / sedative effect, hypnotic effect and anticonvulsant effect, and also has an activating effect on the central nervous system such as antiamnestic effect. The present invention has been completed based on these findings.
即ち本発明は、一般式 〔式中Ｒは炭素数１〜15のアルキル基、又はフェニル基
で置換された炭素数１〜10のアルキル基を表わす〕で示
されるＮ−アシル−２−ピロリドンを少なくとも１種含
有する中枢神経障害治療剤を提供するものである。That is, the present invention has the general formula A central nervous system containing at least one N-acyl-2-pyrrolidone represented by the formula [wherein R represents an alkyl group having 1 to 15 carbon atoms or an alkyl group having 1 to 10 carbon atoms substituted with a phenyl group] It is intended to provide a therapeutic agent for disorders.
なお、本発明でいう中枢神経障害治療剤とは抗痙攣
剤、鎮痛・鎮静剤、催眠剤、抗痴呆剤または向知能剤を
含むものである。The therapeutic agent for central nervous system disorders referred to in the present invention includes anticonvulsants, analgesics / sedatives, hypnotics, anti-dementia agents or nootropic agents.
以下本発明を詳しく説明する。 The present invention will be described in detail below.
本発明の中枢神経障害治療剤の有効成分であるＮ−ア
シル−２−ピロリドンは下記の一般式を有する化合物で
ある ここで、式中Ｒは炭素数１〜15のアルキル基、又はフ
ェニル基で置換された炭素数１〜10のアルキル基を表わ
している。N-acyl-2-pyrrolidone which is an active ingredient of the therapeutic agent for central nervous system of the present invention is a compound having the following general formula. Here, in the formula, R represents an alkyl group having 1 to 15 carbon atoms or an alkyl group having 1 to 10 carbon atoms substituted with a phenyl group.
上記化合物の具体例としては、Ｎ−アセチル−２−ピ
ロリドン、Ｎ−プロピオニル−２−ピロリドン、Ｎ−バ
レリル−２−プロピドン、Ｎ−ブチリル−２−ピロリド
ン、Ｎ−ヘプタノイル−２−ピロリドン、Ｎ−デカノイ
ル−２−ピロリドン、Ｎ−ラウロイル−２−ピロリド
ン、Ｎ−ピバロイル−２−ピロリドン、Ｎ−フェニルア
セチル−２−ピロリドン、Ｎ−フェニルプロビオニル−
２−ピロリドン等があげられる。Specific examples of the above compound include N-acetyl-2-pyrrolidone, N-propionyl-2-pyrrolidone, N-valeryl-2-propidone, N-butyryl-2-pyrrolidone, N-heptanoyl-2-pyrrolidone and N-. Decanoyl-2-pyrrolidone, N-lauroyl-2-pyrrolidone, N-pivaloyl-2-pyrrolidone, N-phenylacetyl-2-pyrrolidone, N-phenylprobionyl-
2-pyrrolidone and the like can be mentioned.
本発明で用いるＮ−アシル−２−ピロリドンは従来か
ら公知の方法で製造することができるが、例えば、２−
ピロリドンとトリエチルアミンをテトロハイドロフラン
に溶解しておき、そこに目的アシル化物に対応する酸ク
ロライドを氷冷下撹拌しつつ徐々に加え反応せしめ、次
いで反応液を約15分間室温で撹拌後、沈澱物を減圧濾過
で除去し、その濾液を減圧濃縮した後、残渣を減圧蒸溜
又は再結晶することによって製造することができる。The N-acyl-2-pyrrolidone used in the present invention can be produced by a conventionally known method.
Pyrrolidone and triethylamine were dissolved in tetrohydrofuran, and the acid chloride corresponding to the target acylated product was gradually added to the solution while stirring under ice-cooling to react, then the reaction solution was stirred at room temperature for about 15 minutes, and then the precipitate Is removed by vacuum filtration, the filtrate is concentrated under reduced pressure, and then the residue is distilled under reduced pressure or recrystallized to produce the compound.
本発明で用いられるＮ−アシル−２−ピロリドンは単
独、又は適当な製剤学的担体と共に投与され、例えば錠
剤、糖衣錠、カプセル剤、液剤もしくはシロップ剤など
の形で経口的に投与される他、注射剤等の形で非経口的
に投与することができる。又その他、軟膏剤や坐剤等の
形で局所的に投与することもできる。The N-acyl-2-pyrrolidone used in the present invention is administered alone or together with a suitable pharmaceutical carrier, and is orally administered in the form of, for example, tablets, dragees, capsules, solutions or syrups. It can be parenterally administered in the form of an injection or the like. Alternatively, it may be locally administered in the form of an ointment or a suppository.
一般に経口投与の場合には、約10〜2,000 mg/1日の投
与量が適当であり、通常100〜500mgで好ましい結果が得
られる。しかし、必要により上記限界を逸脱することも
できる。Generally, in the case of oral administration, a dose of about 10 to 2,000 mg / day is suitable, and a preferable result is usually obtained at 100 to 500 mg. However, if necessary, the above limit can be exceeded.
錠剤、被覆された本発明のＮ−アシル−２−ピロリド
ンを含有する錠剤、糖衣剤丸、及び硬質ゼラチン製カプ
セル剤を製造する際には、医療上許容しうる賦形剤、結
合剤、崩壊剤、基剤等を用いて通常の手段で製剤化すれ
ばよい。In producing tablets, coated tablets containing the N-acyl-2-pyrrolidone of the present invention, sugar-coated pills, and hard gelatin capsules, medically acceptable excipients, binders, disintegration It may be prepared into a pharmaceutical preparation by a conventional means using a drug, a base or the like.
かかる賦形剤としては、例えば錠剤、糖衣丸剤及び硬
質ゼラチン製カプセル剤に対してはラクトース、トウモ
ロコシデンプンもしくはその誘導体、タルク、ステアリ
ン酸もしくはその塩等をあげることができる。Examples of such excipients include lactose, corn starch or derivatives thereof, talc, stearic acid or salts thereof for tablets, sugar-coated pills, and hard gelatin capsules.
硬質ゼラチン製カプセル剤に適する賦形剤としては、
例えば植物油、ロウ、脂肪、半固体または液体のポリオ
ール等があげられる。Suitable excipients for hard gelatin capsules include:
Examples thereof include vegetable oils, waxes, fats, semisolid or liquid polyols, and the like.
溶液及びシロップ剤の製造に適した賦形剤は例えば
水、ポリオール、サッカロース、転化糖、グルコース等
である。Suitable excipients for the production of solutions and syrups are, for example, water, polyols, saccharose, invert sugar, glucose and the like.
非経口的に投与する場合には、１投与量単位５〜500
mgの本発明の化合物を注射用蒸溜水、整理食塩水、プロ
ピレングリコール、デキストロース水溶液等に溶かし、
必要ならば医療上許容しうる融解補助剤を用いて注射剤
とし、投与すればよい。また、本発明で用いる化合物の
組成物は他の成分、例えば着色剤、香味剤、溶解剤、安
定剤、湿潤剤、乳化剤、酸化防止剤また防腐剤をも含有
することができる。なお、必要により他の治療薬効成分
も含有させることができる。When administered parenterally, 1 dose unit 5 to 500
mg of the compound of the present invention is dissolved in distilled water for injection, saline solution, propylene glycol, dextrose aqueous solution, etc.,
If necessary, a medically acceptable melting aid may be used for injection and administration. The composition of the compounds used in the present invention may also contain other ingredients such as colorants, flavors, solubilizers, stabilizers, wetting agents, emulsifiers, antioxidants and preservatives. If necessary, other therapeutically active ingredients can also be included.
本発明で用いる化合物の毒性は低く、例えばＮ−アセ
チル−２−ピロリドンの場合で、マウスのLD50はI.P.
（皮下投与）で5g/Kg、P.O.（経口投与）で10g強/Kg、
またＮ−プロピオニル−２−ピロリドンのマウスLD50は
3.5g/Kg（I.P.）、同じくＮ−バレリル−２−ピロリド
ンは5g/Kg（I.P.）、Ｎ−ラウロイル−２−ピロリドン
は10g強/Kg（I.P.）である。The compounds used in the present invention have low toxicity, for example, in the case of N-acetyl-2-pyrrolidone, the LD 50 of mice is IP
(Subcutaneous administration) 5g / Kg, PO (oral administration) more than 10g / Kg,
The mouse LD 50 of N-propionyl-2-pyrrolidone is
3.5 g / Kg (IP), similarly N-valeryl-2-pyrrolidone is 5 g / Kg (IP) and N-lauroyl-2-pyrrolidone is a little over 10 g / Kg (IP).
以下参考例（Ｎ−アシル−２−ピロリドンの製造
例）、実験例（薬理試験）、実施例（製剤例）をあげて
本発明を具体的に説明するが、本発明はこれ等に限定さ
れるものではない。The present invention will be specifically described below with reference to Reference Examples (Production Examples of N-acyl-2-pyrrolidone), Experimental Examples (Pharmacological Tests), and Examples (Formulation Examples), but the present invention is not limited thereto. Not something.
参考例１ （Ｎ−ブチリル−２−ピロリドンの製造例） ２−ピロリドン59.6g（0.7mol）及びトリエチルアミ
ン70.8g（0.7mol）を、テトラハイドロフラン500mlに溶
解したものに、ブチリルクロライド50g（0.47 mol）を
氷冷下に撹拌しつつ、徐々に加えると、乳白色の沈澱物
が生成する。この反応液をさらに15分間室温で撹拌した
後、沈澱物を減圧濾過により除去する。濾液を減圧濃縮
後、残渣を減圧蒸溜すると沸点86〜87℃（0.5 mmHg）の
透明な蒸溜物が得られた。Reference Example 1 (Production Example of N-butyryl-2-pyrrolidone) 2-pyrrolidone 59.6 g (0.7 mol) and triethylamine 70.8 g (0.7 mol) were dissolved in tetrahydrofuran 500 ml, butyryl chloride 50 g (0.47) (mol) is slowly added with stirring under ice cooling, and a milky white precipitate is formed. After stirring the reaction for an additional 15 minutes at room temperature, the precipitate is removed by vacuum filtration. After the filtrate was concentrated under reduced pressure, the residue was distilled under reduced pressure to obtain a transparent distillate having a boiling point of 86 to 87 ° C (0.5 mmHg).
元素分析の結果は 理論値（％） H:8.44 C:61.91 N:9.03 実測値（％） H:8.52 C:61.94 N:8.75であった。The result of elemental analysis was theoretical value (%) H: 8.44 C: 61.91 N: 9.03 actual value (%) H: 8.52 C: 61.94 N: 8.75.
なお、上記と同様の方法により、Ｎ−アセチル−２−
ピロリドン、Ｎ−プロピオニル−２−ピロリドン、Ｎ−
バレリル−２−ピロリドン、Ｎ−ヘプタノイル−２−ピ
ロリドン、Ｎ−デカノイル−２−ピロリドン、Ｎ−ラウ
ロイル−２−ピロリドン、Ｎ−ピバロイル−２−ピロリ
ドン、Ｎ−フェニルアセチル−２−ピロリドン、Ｎ−フ
ェニルプロビオニル−２−ピロリドン等を得ることがで
きる。In addition, N-acetyl-2-
Pyrrolidone, N-propionyl-2-pyrrolidone, N-
Valeryl-2-pyrrolidone, N-heptanoyl-2-pyrrolidone, N-decanoyl-2-pyrrolidone, N-lauroyl-2-pyrrolidone, N-pivaloyl-2-pyrrolidone, N-phenylacetyl-2-pyrrolidone, N-phenyl Probionyl-2-pyrrolidone and the like can be obtained.
実験例１（予備試験：自発運動測定試験） 夏目製作所のPhotocell counterを使用して実験し
た。本発明の各化合物を0.5％CMC−Na水溶液に懸濁し、
ddY雄性マウス（35〜40g）の腹腔内に投与した。30分後
マウスを１匹ずつ装置内に入れ、30秒後から１分間光束
横断回数を測定した。結果を表−１に示す。Experimental Example 1 (preliminary test: spontaneous locomotion measurement test) An experiment was performed using a Photocell counter manufactured by Natsume Seisakusho. Suspending each compound of the present invention in 0.5% CMC-Na aqueous solution,
It was intraperitoneally administered to ddY male mice (35 to 40 g). After 30 minutes, one mouse was placed in the apparatus, and after 30 seconds, the number of light flux crossings was measured for 1 minute. The results are shown in Table 1.
表−１に示す自発運動量に影響を与えない投与量で以
下の実験を行った。 The following experiment was conducted at a dose that does not affect the locomotor activity shown in Table 1.
実験例２（鎮痛作用試験） 酢酸−writhing法を用いた。本発明の各化合物を0.5
％CMC−Na溶液に懸濁し、これをddY雄性マウス（35〜40
g）腹腔内に投与した。50分後に、0.6％酢酸0.1ml/10g
（体重）を腹腔内に投与し、10,20分後に５分間各マウ
スのwrithing数を測定した。又各群についてwrithing数
の総和を求めた。結果を表−２に示す。Experimental Example 2 (Analgesic test) The acetic acid-writhing method was used. 0.5 of each compound of the present invention
% CMC-Na solution, and suspend it in ddY male mice (35-40
g) It was administered intraperitoneally. 50 minutes later, 0.6% acetic acid 0.1 ml / 10 g
(Body weight) was intraperitoneally administered, and 10 and 20 minutes later, the writhing number of each mouse was measured for 5 minutes. The total writhing number was calculated for each group. Table 2 shows the results.
上表にみるように、本発明化合物の投与によりwrithi
ng数の減少（鎮痛作用）が認められる。この作用は本発
明化合物が鎮痛・鎮痛剤として有用であることを示して
いる。 As shown in the table above, the administration of the compound of the present invention caused writhi
Decreased ng number (analgesic effect) is observed. This action indicates that the compound of the present invention is useful as an analgesic / analgesic agent.
実験例３（催眠延長作用試験） 各化合物を0.5％CMC−Na溶液に懸濁し、これをddY雄
性マウス（35〜40g）の腹腔内に投与した。投与後30分
に、ペントパルビタール45mg/Kgを腹腔内に投与し、正
向反射消失時間及び睡眠時間を測定した。結果を表−３
に示す。Experimental Example 3 (hypnotic extension effect test) Each compound was suspended in a 0.5% CMC-Na solution, and this was intraperitoneally administered to ddY male mice (35 to 40 g). 30 minutes after the administration, pentoparbital 45 mg / Kg was intraperitoneally administered, and the time to eliminate righting reflex and the sleep time were measured. The results are shown in Table-3.
Shown in
表にみるように、本発明化合物の投与によりペントパ
ルビタール睡眠延長効果が認められる。この効果は本発
明化合物が催眠剤として有用であることを示している。 As shown in the table, administration of the compound of the present invention has a pentoparbital sleep-prolonging effect. This effect indicates that the compound of the present invention is useful as a hypnotic agent.
実験例４（抗痙攣作用試験） 各化合物を１％CMC−Na溶液に懸濁し、これをddY雄性
マウス（35〜40g）腹腔内に投与した。投与１時間後
に、痙攣薬としてピクロトキシン5mg/Kg（0.1ml/10g体
重の容量で）を皮下投与し、間代性、強直性痙攣及び死
亡までの時間を測定した。Experimental Example 4 (anticonvulsive activity test) Each compound was suspended in a 1% CMC-Na solution, and this was intraperitoneally administered to a ddY male mouse (35 to 40 g). One hour after administration, picrotoxin 5 mg / Kg (with a volume of 0.1 ml / 10 g body weight) was subcutaneously administered as a convulsant, and the time until clonic, ankylosing convulsions and death was measured.
結果を表−４に示す。 The results are shown in Table-4.
上表にみるように、本発明化合物にはピクロトキシン
により発現された痙攣を抑制し、痙攣による死亡時間の
延長効果が認められる。 As shown in the above table, the compounds of the present invention suppress the convulsions expressed by picrotoxin, and have the effect of prolonging the death time due to convulsions.
この効果は本発明化合物が抗痙攣剤として有用である
ことを示している。This effect indicates that the compound of the present invention is useful as an anticonvulsant.
実験例５（抗健忘作用試験） Ａ）電撃痙攣（ECS）モデル Step−Through型装置を使用した。各化合物を0.5％CM
C−Na溶液に懸濁し、これをddY雄性マウス（20〜25g）
の腹腔内に投与した。１時間後に各マウスを装置の暗室
部に入れ、暗室に移るまでの時間を測定。暗室に入って
から３秒後に30Vの電気ショックを与え学習を行う。こ
の直後に100V,0.4秒のECS（電撃痙攣ショック）処理を
各マウスに施し健忘を起こす。24時間後、再び装置内に
マウスを入れ、暗室に入るまでの時間を測定（５分を上
限とした）した。Experimental Example 5 (anti-amnestic effect test) A) Electric shock convulsion (ECS) model A Step-Through type device was used. 0.5% CM for each compound
Suspend in C-Na solution and use this as a ddY male mouse (20-25g)
Was administered intraperitoneally. One hour later, each mouse was placed in the dark room of the device, and the time required to move to the dark room was measured. 3 seconds after entering the dark room, give a 30V electric shock and learn. Immediately after this, 100 V, 0.4 second ECS (electric shock convulsion shock) treatment is applied to each mouse to cause amnesia. After 24 hours, the mouse was again placed in the apparatus, and the time until entering the dark room was measured (up to 5 minutes).
結果を表−５に示す。 The results are shown in Table-5.
上表にみるように、本発明化合物の投与により抗健忘
作用が認められる。 As seen in the above table, administration of the compound of the present invention has an antiamnestic effect.
この効果は本発明化合物が抗痴呆剤又は向知能剤とし
て有用であることを示している。This effect indicates that the compound of the present invention is useful as an anti-dementia agent or a nootropic agent.
実施例１ カプセル剤 １個当たり Ｎ−アセチル−２−ピロリドン（液状：やや水溶性）
を通常用いられる手段でソフトゼラチンカプセルに充填
する。Example 1 N-acetyl-2-pyrrolidone (liquid: slightly water-soluble) per capsule
Are filled in a soft gelatin capsule by a commonly used means.
実施例３ 以下、常法により下記に示す配合組成にて夫々の製剤
を製造した。Example 3 In the following, each formulation was manufactured by the conventional method with the following blending composition.
シロップ剤 10ml当たり Ｎ−アセチル−２−ピロリドン 200mg 単シロップ 10ml 乳 剤 1000ml当たり Ｎ−ラウロイル−２−ピロリドン（液状：脂溶性）
1g Span 60 30g Tween 80 20g 精製水 1000ml 坐 剤 １個当たり Ｎ−アセチル−２−ピロリドン 200mg ウイテップゾール 1800mg 軟膏剤 1000g当たり Ｎ−アセチル−２−ピロリドン 30g 精製ラノリン 50g サラシミツロウ 50g 白色ワセリン 870g 注射剤 １管10ml当たり Ｎ−アセチル−２−ピロリドン 50mg ポリエチレングリコール 4ml 注射用蒸溜水 6ml 〔発明の効果〕 本発明の特定のＮ−アシル−２−ピロリドンを有効成
分とする中枢神経障害治療剤は、中枢神経に対する抑制
的な作用を利用した鎮痛・鎮静剤、催眠剤又は抗痙攣剤
として有用であるとともに、中枢神経に対する賦活的な
作用を利用した抗痴呆剤又は向知能剤としても有用であ
るというように、中枢神経障害に対し幅広い薬効を持つ
薬剤である。N-Acetyl-2-pyrrolidone 200mg per 10ml syrup N-lauroyl-2-pyrrolidone (liquid: fat-soluble) per 10ml single syrup 1000ml
1g Span 60 30g Tween 80 20g Purified water 1000ml Suppository N-acetyl-2-pyrrolidone 200mg Witepsol 1800mg Ointment 1000g N-acetyl-2-pyrrolidone 30g Purified lanolin 50g Salami beeswax 50g White vaseline 870g Injection Per tube 10 ml N-acetyl-2-pyrrolidone 50 mg Polyethylene glycol 4 ml Distilled water for injection 6 ml [Effect of the invention] A central nervous system therapeutic agent containing the specific N-acyl-2-pyrrolidone of the present invention as an active ingredient is It is useful as an analgesic / sedative agent, hypnotic agent or anticonvulsant agent that uses inhibitory action on nerves, and also as an anti-dementia agent or nootropic agent that uses activating action on central nerves. In addition, it is a drug with a wide range of efficacy against central nervous system disorders.
Claims (5)
で置換された炭素数１〜10のアルキル基を表わす〕 で示されるＮ−アシル−２−ピロリドンを少なくとも１
種含有する中枢神経障害治療剤。1. A general formula [Wherein R represents an alkyl group having 1 to 15 carbon atoms or an alkyl group having 1 to 10 carbon atoms substituted with a phenyl group], and at least one N-acyl-2-pyrrolidone
Seed-containing therapeutic agent for central nervous system disorders.
請求の範囲第１項記載の中枢神経障害治療剤。2. The central nervous system therapeutic agent according to claim 1, wherein the central nervous system therapeutic agent is an anticonvulsant.
特許請求の範囲第１項記載の中枢神経障害治療剤。3. The central nervous system therapeutic agent according to claim 1, wherein the central nervous system therapeutic agent is an analgesic / sedative agent.
求の範囲第１項記載の中枢神経障害治療剤。4. The central nervous system therapeutic agent according to claim 1, wherein the central nervous system therapeutic agent is a sleep agent.
剤である特許請求の範囲第１項記載の中枢神経障害治療
剤。5. The therapeutic agent for central neuropathy according to claim 1, wherein the therapeutic agent for central neuropathy is an anti-dementia agent or a nootropic agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62077569A JP2527958B2 (en) | 1987-04-01 | 1987-04-01 | Central nervous system treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62077569A JP2527958B2 (en) | 1987-04-01 | 1987-04-01 | Central nervous system treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63246328A JPS63246328A (en) | 1988-10-13 |
| JP2527958B2 true JP2527958B2 (en) | 1996-08-28 |
Family
ID=13637646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62077569A Expired - Lifetime JP2527958B2 (en) | 1987-04-01 | 1987-04-01 | Central nervous system treatment |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2527958B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0720930B2 (en) * | 1988-07-09 | 1995-03-08 | 明治製菓株式会社 | Pyrrolidinone compound and cerebral dysfunction improving agent |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0813740B2 (en) * | 1987-02-28 | 1996-02-14 | 麒麟麦酒株式会社 | Antiamnestic |
-
1987
- 1987-04-01 JP JP62077569A patent/JP2527958B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPS63246328A (en) | 1988-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2128160C1 (en) | Trometaminic salt of (+)-(s)-2-(3-benzoylphenyl)propionic acid, method of preparing thereof, and pharmaceutical composition | |
| KR100785182B1 (en) | Gabapentin Analogues for Sleep Disorders | |
| EP0607201A1 (en) | Composition comprising s-oxiracetame for use as nootropic | |
| CA2073084C (en) | The use of sulphur-containing carboxylic acids to combat physiologically-induced excitatory disorders and diseases related thereto as well as allergic diseases and also the preparation of corresponding medicaments | |
| US8049038B2 (en) | Carnitine conjugates of adamantanamines derivatives as dual prodrugs for various uses | |
| JP2001508400A (en) | Isatin derivatives as acetylcholinesterase inhibitors and analgesics | |
| JPS62212322A (en) | Medicinal composition and therapy | |
| JP2526059B2 (en) | Anti-ulcer agent | |
| JP2919867B2 (en) | Antitumor agent | |
| JP2815179B2 (en) | Anti-inflammatory and / or anti-allergic agent | |
| EP0768084A1 (en) | Cancerous metastasis inhibitor | |
| JP2527958B2 (en) | Central nervous system treatment | |
| CN110590839B (en) | Levatinib derivative and preparation method and application thereof | |
| JP2919870B2 (en) | Liver damage inhibitor | |
| CN109180679A (en) | A kind of N- substituted pyrazolecarboxylic simultaneously [3,4-d] pyrimidinones and its preparation method and application | |
| FR2610932A1 (en) | NOVEL PIPERAZINECARBOXYLIC ACID, ITS PREPARATION AND ITS USE AS A MEDICINAL PRODUCT | |
| CA2459719C (en) | Pharmaceutical composition comprising gamma-butyrobetaine | |
| JP2567593B2 (en) | Imidazolidinetrione derivative and therapeutic agent for allergic disease containing the compound as an active ingredient | |
| JPH11504041A (en) | Biologically active ureide derivatives useful for the treatment of multiple sclerosis | |
| JP3450399B2 (en) | Angiogenesis inhibitor | |
| CN114349665B (en) | Metformin pyroglutamic acid crystal and preparation method and application thereof | |
| KR920001762B1 (en) | Agent for treating hyperuricemia | |
| JPH02304058A (en) | Xanthocillin x monomethyl ether derivative and antineoplastic agent | |
| JPH05112463A (en) | Therapeutic agent for cataract | |
| JP2843944B2 (en) | Bile medicine |